Donate now
EN
1 April 2015

IARC NCI Tumour Seminars Difficult questions in renal cancer research

Introductions and Presentation of the first draft of the ‘difficult questions’

Christopher P. Wild, Watch video

Session 1 – Descriptive and analytical epidemiology of renal cancer

Descriptive epidemiology and an overview of non-genetic factors for renal cancer

Ariana Znaor, Watch video
View slides

Personalized risk prediction for renal cell carcinoma

Xifeng Wu

Do circulating vitamins drive renal cancer incidence and survival?

Mattias Johansson, Watch video
View slides

Session 2 – Molecular and genetic epidemiology of renal cancer

Genetics of obesity, diabetes and metabolic syndrome – are there clues for renal cancer?

Tim Frayling, Watch video
View slides

Metabolic factors associated with renal cancer

Pär Stattin, Watch video
View slides

Highly penetrant kidney cancer syndromes

Marston Linehan

Clinical genetics and management of hereditary renal and adrenal cancer susceptibility syndromes

Kate Nathanson, Watch video
View slides

Common germline variation for renal cancer – results of large GWAS

Mark Purdue

 

Session 3 – Genomics of renal cancer

Landscape of somatic alterations in kidney cancer – an integrated analysis

Chad Creighton, Watch video
View slides

Renal cancer evolution – accessing the time axis

Su Kit Chew, Watch video
View slides

TCEB1 mutated tumors, a novel entity of clear cell renal carcinomas

Seishi Ogawa, Watch video
View slides

Genomic signatures for environmental exposures – the CAGEKID study

Ghislaine Scélo, Watch video
View slides

Chromatin alterations in RCC

Ian Davis, Watch video
View slides

Integrating proteomics with genomics – biomarker and therapeutic target discovery

Roz Banks, Watch video
View slides

Genomics of pediatric renal tumors

Elizabeth J Perlman

Session 4 – Therapeutic Issues in renal cancer

Genomics and management of renal cancer: move in translation

Olivier Cussenot, Watch video
View slides

Optimal targeting of the PD-1/PD-L1 Pathway in Metastatic RCC

David F. McDermott, Watch video
View slides

How to rationalize intermittent schedule and dose adaptation with VEGF inhibitors?

Bernard Escudier, Watch video
View slides

Close Reading Mode
UP